molecules of the month


oral selective ER degrader and antagonist

in Ph. IIb studies for ER+ breast cancer

from ligand-based design and opt.

J. Med. Chem., Sep. 29, 2020

AstraZeneca, Cambridge, UK / Waltham, MA

Structure of AZD9833, a selective oestrogen receptor degrader (SERD)
1 min read

AZD9833 is a potent, orally available selective estrogen receptor degrader (SERD) and antagonist in development for breast cancer. The only approved SERD is the widely used fulvestrant, which is given by monthly intramuscular injection and may have submaximal antitumor activity. A safe, oral alternative has been highly sought after and the oncology community looks forward to clinical efficacy data from the AZD team.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: